

Osteoporosis

Delivery Need By:	Deliver to:	🗆 Patien	t's Home	Physician's Office	🗆 Other	
PATIENT I	PRESCRIBER INFORMATION					
Patient Name:		🗆 Male	Prescriber	's Name:		
Address:		🗆 Female	Office Cor	ntact Name:		
City: 5			Address:			
Phone Number:				State:		
Email Address: Last Four of Social:				mber: #:		

INSURANCE – PLEASE FAX COPY OF PRESCRIPTION CARD FRONT & BACK

CLINICAL INFORMATION									
Diagnosis:		Has the patient been treated previously for this condition?							
ICD-10 Code: _		🗆 Yes 🗆 No							
Height:	ft inches Weight: lbs	Medications Failed:							
Allergies:		Medications On:							
Other Notes.									
PRESCRIPTION INFORMATION									
Medication:	Dosage/Strength:	Directions:	Quantity:	Refills:					
Evenity ®	□ 105 mg/1.17ml prefilled syringe	 Inject 210mg (two syringes one after the other) once a month for twelve months SC by a health care provider 	 □ 2 syringes (30 day supply) □ 6 syringes (90 day suppy) 						
Forteo [®]	□ 600mcg/2.4ml pen	□ Inject 20mcg SC once daily	 1 Device (4 week supply) 3 devices (12 week supply) Other 						
□ 31G Pen Needles □ 5mm □ 6 mm □ 8mm		□ Use with Forteo® as directed	□ 28 day supply □ 84 day supply						
Prolia ®	□ 60 mg/1ml prefilled syringe	□ Inject 60mg SC every 6 months	□ 1 syringe						
Reclast®	□ 5 mg/100 ml ready-to-infuse solution	🗆 Infuse 5 mg once a year	□ vials						
Tymlos®	🗆 2000mcg/Ml, 1.5ML Pen	□ Inject 80mcg SC once daily	 1 device (30 day supply) 3 devices (90 day supply) Other 						
□ 31G Pen Needles □ 5mm □ 6 mm □ 8mm		\Box Use with Tymlos $^{\! \circ}$ as directed	□ 30 day supply □ 90 day supply						
Other									
□ Patient is interested in patient support programs □ Ancillary supplies provided for administration									

Physician Signature:

Date: ___

www.noblehealthservices.com

Important Notice: This communication contains information that is confidential and protected from disclosure. If the reader of this message is not the intended recipient, employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this communication is strictly prohibited. If you have received this communication in error, please reply to the sender that you have received the message in error and destroy this copy.

v. Q420192g